Invitro assessment of antiretroviral drugs demonstrates potential for ototoxicity

Hearing Research

Volumn 310, Issue , 2014, Pages 27-35

  Thein, Pru ^a   Kalinec, Gilda M ^a   Park, Channy ^a   Kalinec, Federico ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARNITINE; CASP3 PROTEIN, HUMAN; CASP7 PROTEIN, HUMAN; CASPASE 3; CASPASE 7; DRUG COMBINATION;

CELL DEATH; CELL LINE; CHEMICALLY INDUCED; CORTI ORGAN; DRUG COMBINATION; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; HEARING IMPAIRMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; METABOLISM; PATHOLOGY; TOXICITY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARNITINE; CASPASE 3; CASPASE 7; CELL DEATH; CELL LINE; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; HEARING LOSS; HUMANS; ORGAN OF CORTI;

EID: 84893857259     PISSN: 03785955     EISSN: 18785891     Source Type: Journal    
DOI: 10.1016/j.heares.2014.01.005     Document Type: Article

References (33)

1. Bektas D., Martin G.K., Stagner B.B., Lonsbury-Martin B.L. Noise-induced hearing loss in mice treated with antiretroviral drugs. Hear Res. 2008, 239:69-78.
2. Benbrik E., Chariot P., Bonavaud S., Ammi-Said M., Frisdal E., Rey C., Gherardi R., Barlovatz-Meimon G. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J.Neurol. Sci. 1997, 149:19-25.
3. Bruning A., Burger P., Vogel M., Rahmeh M., Gingelmaiers A., Friese K., Lenhard M., Burges A. Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis. Cancer Biol. Ther. 2009, 8:226-232.
4. De Simone C., Famularo G., Tzantzoglou S., Trinchieri V., Moretti S., Sorice F. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral L-carnitine. AIDS 1994, 8:655-660.
5. De Simone C., Tzantzoglou S., Famularo G., Moretti S., Paoletti F., Vullo V., Delia S. High dose L-carnitine improves immunologic and metabolic parameters in AIDS patients. Immunopharmacol. Immunotoxicol. 1993, 15:1-12.
6. Degterev A., Yuan J. Expansion and evolution of cell death programmes. Nat. Rev. Mol. Cell. Biol. 2008, 9:378-390.
7. FDA Anti-retrovirus Guidelines 2012, (Posted 08/14/2013; verified 08/14/2013). http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm.
8. Feng J.Y., Johnson A.A., Johnson K.A., Anderson K.S. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J.Biol. Chem. 2001, 276:23832-23837.
9. Fink S.L., Cookson B.T. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect. Immun. 2005, 73:1907-1916.
10. Gazzard B.G., Anderson J., Babiker A., Boffito M., Brook G., Brough G., Churchill D., Cromarty B., Das S., Fisher M., Freedman A., Geretti A.M., Johnson M., Khoo S., Leen C., Nair D., Peters B., Phillips A., Pillay D., Pozniak A., Walsh J., Wilkins E., Williams I., Williams M., Youle M. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008, 9:563-608.
11. Hammer S.M., Eron J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., Cahn P., Fischl M.A., Gatell J.M., Hirsch M.S., Jacobsen D.M., Montaner J.S., Richman D.D., Yeni P.G., Volberding P.A. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-570.
12. Harris T., Bardien S., Schaaf H.S., Petersen L., De Jong G., Fagan J.J. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. SAfr. Med. J. 2012, 102:363-366.
13. Hart A.M., Wiberg M., Youle M., Terenghi G. Systemic acetyl-L-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma. Exp. Brain Res. 2002, 145:182-189.
14. Hart A.M., Wilson A.D., Montovani C., Smith C., Johnson M., Terenghi G., Youle M. Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004, 18:1549-1560.
15. Herzmann C., Johnson M.A., Youle M. Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin. Trials 2005, 6:344-350.
16. Kalinec G., Fernandez Zapico M., Urrutia R., Chen S., Esteban-Cruciani N., Kalinec F. Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss. Proc. Natl. Acad. Sci. USA 2005, 102:16019-16024.
17. Kalinec G.M., Webster P., Lim D.J., Kalinec F. Acochlear cell line as an invitro system for drug ototoxicity screening. Audiol. Neurootol. 2003, 8:177-189.
18. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell. Biol. 2007, 8:741-752.
19. Marra C.M., Wechkin H.A., Longstreth W.T., Rees T.S., Syapin C.L., Gates G.A. Hearing loss and antiretroviral therapy in patients infected with HIV-1. Arch. Neurol. 1997, 54:407-410.
20. Monte S., Fenwick J.D., Monteiro E.F. Irreversible ototoxicity associated with zalcitabine. Int. J. STD AIDS 1997, 8:201-202.
21. Moretti S., Famularo G., Marcellini S., Boschini A., Santini G., Trinchieri V., Lucci L., Alesse E., De Simone C. L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine. Antioxid. Redox Signal 2002, 4:391-403.
22. Moretti S., Alesse E., Di Marzio L., Zazzeroni F., Ruggeri B., Marcellini S., Famularo G., Steinberg S.M., Boschini A., Cifone M.G., De Simone C. Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: a pilot study. Blood 1998, 91:3817-3824.
23. Parrish A.B., Freel C.D., Kornbluth S. Cellular mechanisms controlling caspase activation and function. Cold Spring Harb. Perspect. Biol. 2013, 5:a008672.
24. Riddler S.A., Haubrich R., DiRienzo A.G., Peeples L., Powderly W.G., Klingman K.L., Garren K.W., George T., Rooney J.F., Brizz B., Lalloo U.G., Murphy R.L., Swindells S., Havlir D., Mellors J.W. Class-sparing regimens for initial treatment of HIV-1 infection. N.Engl. J. Med. 2008, 358:2095-2106.
25. Simdon J., Watters D., Bartlett S., Connick E. Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature. Clin. Infect. Dis. 2001, 32:1623-1627.
26. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J., Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N.Engl. J. Med. 1999, 341:1865-1873.
27. Venhoff N., Setzer B., Melkaoui K., Walker U.A. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir. Ther. 2007, 12:1075-1085.
28. Vogeser M., Colebunders R., Depraetere K., Van Wanzeele P., Van Gehuchten S. Deafness caused by didanosine. Eur. J. Clin. Microbiol. Infect. Dis. off. Publ. Eur. Soc. Clin. Microbiol. 1998, 17:214-215.
29. Youle M. HIV-associated antiretroviral toxic neuropathy (ATN): a review of recent advances in pathophysiology and treatment. Antivir. Ther. 2005, 10(Suppl.2):M125-M129.
30. Youle M. Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs 2007, 21(Suppl.1):25-30. Discussion 45-6.
31. Youle M., Osio M. Adouble-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 2007, 8:241-250.
32. Zha B.S., Studer E.J., Zha W., Hylemon P.B., Pandak W., Zhou H. Highly active antiretroviral therapy (HAART) and metabolic complications. Recent Translational Research in HIV/AIDS 2011, 253-274. W.T. PY (Ed.).
33. Zhou H. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Meth. Enzymol. 2011, 490:107-119.